Recent studies have demonstrated that MST1/2 deletion significantly promotes the development of lung cancer.[36, 37, 38] Additionally, research on the traditional Chinese medicine component Neferine has shown that it can effectively inhibit lung cancer cell development by downregulating TGF‐β and modulating MST1/ROS‐induced pyroptosis.[39] These findings suggest that MST1/2 holds potential as an unexplored drug target, with MST1/2 activators offering a promising avenue for NSCLC prevention. Here, TGFB1 is linked to lung carcinoma.